Submission

X v Amstelveen Equity Trust BV et al. Holds (wrongly imo) that Article 26 Brussels Ia submission applies to non-EU defendants, too. Then grants an A33-34 stay viz Dutch defendants and, in a show of cakeism, a ‘metoo’ stay against the Turkish defendants. – Go Health Pro

by
X v Amstelveen Equity Trust BV et al. Holds (wrongly imo) that Article 26 Brussels Ia submission applies to non-EU defendants, too. Then grants an A33-34 stay viz Dutch defendants and, in a show of cakeism, a ‘metoo’ stay against the Turkish defendants. – Go Health Pro

If you do use the blog for research or database purposes, citation would be appreciated, to the blog as a whole and /or to specific blog posts. Many have suggested I should turn the blog into a paid for, subscription service however I have resisted doing so. Proper reference to how the blog is useful … Read more

Zacks Small Cap Research – MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT On March 17, 2025, Monogram (NASDAQ:MGRM) announced that the FDA has granted 510(k) clearance for its Monogram mBôs TKA System. This determination means that the company can move forward with upgrades and begin the commercialization process. The mBôs TKA System is designed to deliver … Read more

Zacks Small Cap Research – MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its 510(k) premarket filing submission for the semi-active mBôs TKA System. … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Announces Submission of DrugSorb-ATR Application to the FDA – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT DrugSorb-ATR Submission On October 1, 2024, CytoSorbents (NASDAQ:CTSO) announced the submission of its DrugSorb-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (FDA) on September 27, 2024. The goal of this product is to reduce the severity of perioperative … Read more